ADAURA

NCT02511106 📎

Regimen

Experimental
osimertinib 3 yr adjuvant
Control
placebo

Population

Stage IB-IIIA completely resected EGFR-mut NSCLC

Key finding

DFS HR 0.20 (0.14-0.30) in stage II-IIIA; OS HR 0.49 (0.33-0.73) in updated analysis

Source: PMID 32955177

Timeline

  • Enrollment start: 2015-10-21 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.162)
  • CSCO NSCLC 2025 ⚠️ OCR source